EGFR复合少见突变阳性的非小细胞肺癌患者的临床特征及疗效分析  

The Clinical Characteristics and Treatment Response of Patients with EGFR Complex Rare Mutations

作　　者：李红霞 林海峰 陶虹[1] 吴卫华[1] 郭丽丽[1] 仝丽[1] 武玮[1] 车南颖[1] 刘喆[1] Li Hongxia;Lin Haifeng;Tao Hong;Wu Weihua;Guo Lili;Tong Li;Wu Wei;Che Nanying;Liu Zhe(Department of Oncology,Beijing Chest Hospital,Capital Medical University,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京胸科医院肿瘤科,101149

出　　处：《结核病与胸部肿瘤》2021年第1期34-38,共5页Tuberculosis and Thoracic Tumor

基　　金：北京市希思科肿瘤学研究基金会希思科-恒瑞肿瘤研究基金(编号:Y-HR2018-119)。

摘　　要：目的分析非小细胞肺癌患者中表皮生长因子受体(EGFR)突变为包含少见突变的复合突变患者的临床特征与治疗效果,为EGFR复合少见突变阳性的非小细胞肺癌患者的治疗提供依据。方法回顾性分析22例EGFR复合少见突变阳性的非小细胞肺癌患者的病历资料及治疗经过。比较患者EGFR基因突变类型、临床资料特征及治疗效果。结果在我院2014年-2018年病理科检测的EGFR突变阳性的3224名患者当中,EGFR复合突变共147例,占比为4.56%,而复合少见突变患者共27例,占比0.84%。晚期复合少见突变患者中有11名使用EGFR酪氨酸激酶抑制剂(TKI)治疗,对这些患者的治疗用药及疗效分析后,使用一代TKI治疗患者6人,中位无进展生存时间(PFS)为8.4个月,二代TKI治疗患者5人,中位PFS为7.2月,两组之间无明显统计学差别。结论EGFR复合少见突变的患者使用一代或二代EGFR-TKI治疗疗效无明显差别。.Objective To analyze clinical characteristics and treatment outcomes of the non-small cell lung cancer patients,who had EGFR complex rare mutations,to get more information and give better treatment for these patients.Methods The clinical data and treatment of 22 patients who had EGFR complex rare mutations in our hospital were collected and analyzed retrospectively.Results There are 3224 EGFR mutation positive patients in all the tested samples in our hospital during 2014 to 2018.There was the complex mutations positive in 147 patients(4.56%)and 27 patients(0.84%)with complex rare mutations positive.In these complex rare mutation positive patients,there were 11 patients had received EGFR-TKI treatment.Six patients used first generation TKI as treatment,and the medium PFS was 8.4 months.The other 5 patients used second generation TKI as treatment and the medium PFS was 7.2 months.There was no significant difference between these two groups.Conclusion For the EGFR complex rare mutations positive patients,there is no difference between the treatment of first or second generation TKI.

关 键 词：非小细胞肺癌 表皮生长因子受体 复合少见突变 

分 类 号：R73[医药卫生—肿瘤]